OTIC Otonomy

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting, to be held virtually during February.

Otonomy is participating in a workshop entitled “Translational delivery approaches for inner ear therapies” that will be held from 11 a.m. to 1 p.m. ET on February 11. The Otonomy presentation topic and presenter are as follows:

  • “Factors in intratympanic drug delivery for the inner ear” by Bonnie Jacques, Ph.D.

All other presentations are posters that will be available for registered attendees via the conference website beginning on February 1.

Poster presentations by Otonomy authors:

  • “OTO-825 gene therapy rescues hearing loss and cochlear degeneration in a clinically relevant inducible mouse model of GJB2 congenital hearing loss” by Mathur et al. (poster #323)



  • “AAV-mediated gene therapy with OTO-825 rescues hearing loss and cochlear degeneration in a clinically relevant tissue specific mouse model of GJB2 congenital hearing loss” by Uribe et al. (poster #330)



  • “Identification and characterization of a novel therapeutic class of otoprotectants for the prevention of cisplatin-induced hearing loss”, poster by Fernandez et al. (poster #527)

Poster presentations by Otonomy collaborators:

  • “The Trkb-selective agonist monoclonal antibody M3 promotes in vivo spiral ganglion cell survival in deafened guinea pigs” by Vink et al. (poster #514)



  • “Development of an enhanced screening assay to distinguish between hair cell regeneration and otoprotection” by Singh et al. (poster #751)

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit .

Contacts:

Media Inquiries:

Spectrum Science

Chloé-Anne Ramsey

Vice President

404.865.3601

Investor Inquiries:

Westwicke ICR

Robert H. Uhl

Managing Director

858.356.5932



EN
25/01/2022

Underlying

OTICOtonomy

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Otonomy

 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Announces Change in Stock Exchange Listing

Otonomy Announces Change in Stock Exchange Listing SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company’s shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications ...

December 22, 2022 1 EN
 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Provides Corporate Update

Otonomy Provides Corporate Update SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of...

December 19, 2022 1 EN
 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corp...

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update Evaluation of strategic options to realize value from pipeline is ongoing SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no c...

November 10, 2022 1 EN
 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Dos...

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex dose-response relationship that has been observed with neurotrophinsOtonomy intends to explore strategic options to advance and realize value from its pipeline including both OTO-413 and OTO-825 SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical c...

October 13, 2022 1 EN
 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Pati...

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 following positive Phase 2a results in April 2022; top-line results for evaluation of higher dosing still expected in fourth quarter of 2022 SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical com...

August 1, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch